ROKIT Healthcare, an artificial intelligence (AI)-based regenerative treatment platform corporation, will be listed on the KOSDAQ market this week. D'Alba Global and IntoCell, which attracted strong demand from institutional investors, are set to begin general subscriptions for their listings.
According to the financial investment industry on the 11th, ROKIT Healthcare will start trading stocks on the KOSDAQ market on the 12th. ROKIT Healthcare is a bio corporation specializing in technology to regenerate human tissues such as skin, cartilage, and kidneys. Previously, the final public offering price was confirmed at 11,000 won, the lower end of the desired range (band) based on the results of demand forecasting for institutional investors.
Recently, corporations like DN Solutions and LOTTE Global Logistics, which were attempting to list on the securities market (KOSPI), have withdrawn their listings due to poor demand forecast results. Meanwhile, d'Alba Global, the only one to succeed in attracting investment, is conducting general subscriptions until the 12th. The final public offering price is set at 66,300 won, the upper end of the band.
BioTech corporation IntoCell will also accept subscriptions on the 13th and 14th. IntoCell conducted a demand forecast until the 8th. The public offering price band is set at 12,500 won to 17,000 won. The underwriter plans to announce the confirmed public offering price on the 12th, one day before the general subscription.
Kistron and Lincsolution will enter demand forecasting for institutional investors this week. Kistron is a manufacturer of wire for electronic components and a subsidiary of KISWIRE. The public offering price band is set at 3,100 won to 3,600 won. 3D printing company Lincsolution will begin its demand forecasting on the 16th, with a public offering price band of 20,000 won to 23,000 won.
Aukrypto plans to conduct demand forecasting until the 15th to confirm its final public offering price. The public offering price band is set at 18,700 won to 22,000 won.